Updated
Reviewed
Aug. 01, 2019
Appendix B: Panel Roster and Financial Disclosures
Herpes (HHV-8/CMV)
Member | Financial Disclosure | ||
---|---|---|---|
Company | Relationship | ||
Durand, Christine | Johns Hopkins | AbbVie | Research Support |
Gilead | Grant Review Committee | ||
ViiV Healthcare | Research Support | ||
Gnann, John | Medical University of South Carolina | BioCryst | Data and Safety Monitoring Board Member |
GlaxoSmithKline | Data and Safety Monitoring Board Member | ||
Holland, Gary | University of California, Los Angeles | None | N/A |
Johnston, Christine* | University of Washington | Sanofi-Pasteur | Research Support |
UpToDate | Royalties | ||
Parsons, Christopher | Pardee Hospital, University of North Carolina Health Systems | None | N/A |
Phipps, Warren | University of Washington School of Medicine | None | N/A |
Ross, Shannon | University of Alabama at Birmingham | Children’s Hospital of Alabama Kaul Pediatric Research Institute | Research Support |
Merck | Advisory Board | ||
Meridian Bioscience | Educational Webinar | ||
Roche | Advisory Board | ||
Van Wagoner, Nicholas | University of Alabama at Birmingham | Genocea | Research Support |
Sanofi-Pasteur | Research Support | ||
Wohl, David | University of North Carolina at Chapel Hill | Gilead | Research Support, Consultant, Speaking Compensation |
Janssen | Speaking Compensation | ||
Merck | Research Support, Speaking Compensation | ||
ViiV Healthcare | Research Support, Speaking Compensation | ||
*Group lead Note: Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019. |
Download Guidelines
- Full GuidelinePDF (3.78 MB)
- Drug Tables OnlyPDF (481.21 KB)
- Section OnlyPDF (337.79 KB)
- Full GuidelinePDF (3.78 MB)
- Drug Tables OnlyPDF (481.21 KB)